Abstract：OBJECTIVE: To study the protocol of construction of a KCNQ2-c.812G>T mutant and it′s eukaryotic expression vector, the c.812G>T (p.G271V) mutation which was detected in a Chinese pedigree of benign familial infantile convulsions, and to examine the expression of mutant protein in human embyonic kidney (HEK) 293 cells. METHODS: A KCNQ2 mutation c.812G>T was engineered on KCNQ2 cDNAs cloned into pcDNA3.0 by sequence overlap extension PCR and restriction enzymes. HEK293 cells were co-transfected with pRK5-GFP and KCNQ2 plasmid (the wild type or mutant) using lipofectamine and then subjected to confocal microscopy. The transfected cells were immunostained to visualize the intracellular expression of the mutant molecules. RESULTS: Direct sequence analysis revealed a G to T transition at position 812. The c.812G>T mutation was correctly combined to eukaryotic expressive vector pcDNA3.0 and expressed in HEK293 cells. Immunostaining of transfected cells showed the expression of both the wild type and mutant molecules on the plasma membrane, which suggested that the c.812G>T mutation at the pore forming region of KCNQ2 channel did not impair normal protein expression in HEK293 cells. CONCLUSIONS: Successful construction of mutant KCNQ2 eukaryotic expression vector and expression of KCNQ2 protein in HEK293 cells provide a basis for further study on the functional effects of convulsion-causing KCNQ2 mutations and for understanding the molecular pathogenesis of epilepsy.
ZHOU Xi-Hui,HUI Zhi-Yan,SHI Rui-Ming et al. Site-directed mutagenesis and protein expression of KCNQ2 gene associated with neonatal convulsions[J]. CJCP, 2011, 13(8): 611-616.
［1］Tang B, Li H, Xia K, Jiang H, Pan Q, Shen L, et al. A novel mutation in KCNQ2 gene causes benign familial neonatal convulsions in a Chinese family［J］. J Neuro Sci, 2004, 221(1-2): 31-34.
［3］Miceli F, Soldovieri MV, Martire M, Taglialatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs［J］. Curr Opin Pharmacol, 2008, 8(1): 65-74.
［4］Volkers L, Rook MB, Das JH, Verbeek NE, Groenewegen WA, van Kempen MJ, et al. Functional analysis of novel KCNQ2 mutations found in patients with benign familial neonatal convulsions［J］. Neurosci Lett, 2009, 462(1): 24-29.
［5］Viadero MT, Rubín E, Amigo T, González-Lamu~no D. Three generations of hereditary long-QT syndrome with complete penetrance caused by the p.G316E KCNQ1 mutation［J］. Pediatr Cardiol, 2011, 32(1): 102-104.
［6］Otto JF, Yang Y, Frankel WN, White HS, Wilcox KS. A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons［J］. J Neurosci, 2006, 26(7): 2053-2059.
［7］Heron SE, Cox K, Grinton BE, Zuberi SM, Kivity S, Afawi Z, et al. Deletions or duplications in KCNQ2 can cause benign familial neonatal seizures［J］. J Med Genet, 2007, 44(12): 791-796.
［8］Uehara A, Nakamura Y, Shioya T, Hirose S, Yasukochi M, Uehara K. Altered KCNQ3 potassium channel function caused by the W309R pore-helix mutation found in human epilepsy［J］. J Membr Biol, 2008, 222(2): 55-63.
［9］Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family［J］. Nat Genet, 1998, 18(1): 53-55.
［10］Sugiura Y, Nakatsu F, Hiroyasu K, Ishii A, Hirose S, Okada M, et al. Lack of potassium current in W309R mutant KCNQ3 channel causing benign familial neonatal convulsions (BFNC)［J］. Epilepsy Res, 2009, 84(1): 82-85.
［11］Seebohm G, Scherer CR, Busch AE, Lerche C. Identification of specific pore residues mediating KCNQ1 inactivation. A novel mechanism for long QT syndrome［J］. J Biol Chem, 2001, 276(17): 13600-13605.
［12］Seebohm G, Pusch M, Chen J, Sanguinetti MC. Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels［J］. Circ Res, 2003, 93(10): 941-947.
［13］Dedek K, Fusco L, Teloy N, Steinlein OK. Neonatal convulsion and epileptic encephalopathy in an Italian family with a missense mutation in the fifth transmembrane region of KCNQ2［J］. Epilepsy Res, 2003, 54(1): 21-27.
［14］Borgatti R, Zucca C, Cavallini A, Ferrario M, Panzeri C, Castaldo P, et al. A novel mutation in KCNQ2 associated with BFNC, drug resistant epilepsy, and mental retardation［J］. Neurology, 2004, 63(1): 57-65.
［16］Ishii A, Fukuma G, Uehara A, Miyajima T, Makita Y, Hamachi A, et al. A de novo KCNQ2 mutation detected in nonfamilial benign neonatal convulsions［J］. Brain Dev, 2009, 31(1): 27-33.
［17］Neubauer BA, Waldegger S, Heinzinger J, Hahn A, Kurlemann G, Fiedler B, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes［J］. Neurology, 2008, 71(3): 177-183.
［18］Lange W, Geissend-rfer J, Schenzer A, Grtzinger J, Seebohm G, Friedrich T, et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels［J］. Mol Pharmacol, 2009, 75(2): 272-280.
